Tue, Jul 29, 2014, 8:19 AM EDT - U.S. Markets open in 1 hr 11 mins


% | $
Click the to save as a favorite.

Echo Therapeutics, Inc. Message Board

  • investor1579 investor1579 Jun 4, 2012 6:24 PM Flag

    8 1/2 not bad!

    View Document

    Echo Therapeutics (ECTE/$1.9 | Price Target: $8.5) Nathan Cali ncali@noblefcm.com | (561) 994-5723
    Buying a First in Class Opportunity at a Discount

    Rating: BUY
    On June 8th 2012 the American Diabetes Association 72nd Scientific Session will take place in Philadelphia ; More than 14,000 scientists, physicians and other healthcare professionals from around the globe will gather to share cutting edge research
    Echo Therapeutics is expected to present data from "Symphony", a leading continuous glucose monitoring device; oral presentation to demonstrate mechanism of action efficiencies, accuracy, safety, in type 1/2 diabetic patients in a clinic setting
    Also on June 8th, data from a comparative analysis will be reported comparing the three FDA approved CGM devices; Medtronic (MDT: Not Rated) Minimed Guardian, Abbott Labs (ABT: Not Rated) Freestyle Navigator, Dexcom (DXCM: Not Rated) Seven Pl
    In our view, Echo's device is superior based upon the demonstrated combination of safety and efficacy, cost estimates, ease of use, and targeted market opportunity (only non-invasive device, no CGM device approved in hospital)
    Buy, price target $8.50; trading at a significant discount (~90%) compared to that of a pure play competitor DexCom (DXCM: Not Rated); low technology risk product proof-of-concept demonstrated, data from IDE study 2012, CE mark approval expected 2013

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.06+0.04(+1.98%)Jul 28 3:57 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.